Navigation Links
Childhood Epilepsy Global Clinical Trials Review, H2, 2015
Date:1/21/2016

LONDON, Jan. 21, 2016 /PRNewswire/ -- Childhood Epilepsy Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, "Childhood Epilepsy Global Clinical Trials Review, H2, 2015" provides an overview of Childhood Epilepsy clinical trials scenario. This report provides top line data relating to the clinical trials on Childhood Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Childhood Epilepsy Global Data Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Download the full report: https://www.reportbuyer.com/product/3565259/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. 1 in 3 two-year-olds in the United States have not received all recommended childhood vaccines, study finds
2. Pennsylvania Department of Health Opens Application Process for Research Funding to Treat Childhood Seizures
3. 69% of Doctors Say Parents are Completely or Mostly to Blame for Childhood Obesity
4. Childrens Hospitals Shift from CT Scans for Common Childhood Health Problems
5. COLA Accreditation Renewed for Moleculera Labs Testing Services for Childhood Autoimmune Conditions Affecting Brain and Behavior
6. Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness in Childhood Cancer
7. Disrupting Tumor Cell "Microenvironment" Suggests A New Way To Treat A Prevalent Childhood Leukemia
8. MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma
9. Childhood Obesity Need Not Last a Lifetime, says Beverly Hills Physicians
10. Eisai Presents Data on Perampanel and First and Largest U.S. Study on Caregiver Burden in Epilepsy at the 69th Annual American Epilepsy Society Meeting
11. Epilepsy Drugs Market in Europe - Market Analysis 2015-2019 - Reportlinker Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2019)... ... 16, 2019 , ... Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today ... Series B is led by Kairos Ventures, with DEFTA Partners, Tech Coast Angels, and ... to expand the company’s ongoing Phase 1 / 2 clinical trial and fund development ...
(Date:5/16/2019)... , ... May 16, 2019 , ... ... and Dr. Peter D. Caie, Senior Research Fellow at St. Andrew University, UK ... EDT (2pm BST/UK) to learn about a deep learning based image analysis solution ...
(Date:5/15/2019)... ... May 15, 2019 , ... E.M.M.A. ... compliance services for the Medical Device industry, will be participating in a panel ... growing digital device field. Also, EMMA International will be delivering a course on ...
Breaking Medicine Technology:
(Date:5/14/2019)... ... May 14, 2019 , ... Relatient, Inc., a ... eRegistration and Check-In solution , a new product launched to reduce patient wait ... on Relatient’s Patient Engagement platform introducing earlier touch points on the ...
(Date:5/14/2019)... ... May 14, 2019 , ... A coalition ... the world’s biggest health issues – ‘big data’. At a news conference today, ... Research Centre), Stanford University and Southern Methodist University (SMU) announced the U.S. launch ...
(Date:5/14/2019)... ... May 14, 2019 , ... Forty-two billion dollars – just ... according to market analysis company Orbis Research. “Treatments certainly can help,” notes Angie ... PC , “but for our skin, there’s free super-potent anti-aging care available: It’s ...
(Date:5/14/2019)... ... May 14, 2019 , ... ChoiceSpine ... clearance from the U.S. Food and Drug Administration (FDA) to market TIGER SHARK ... a two-screw configuration, for use together or separately in cervical spinal fusion procedures. ...
(Date:5/14/2019)... YORK (PRWEB) , ... May 14, 2019 , ... Dr. ... for 20 years. Recently he acquired the FX 635 cold laser therapy device, becoming ... working on integrating this cutting edge laser with multiple FDA clearances for treating pain ...
Breaking Medicine News(10 mins):